RxMD Announces Development Collaboration with GlycoRegImmune Inc.

-- Agreement establishes new model for early-stage drug development --

-- Focus on treatments for inflammatory/autoimmune conditions based on NK T cell targeted technologies --

SAN DIEGO--(BUSINESS WIRE)-- RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.

Under the agreement, RxMD will use its global drug development expertise, including its team of physician-scientists in Chennai, India, to advance GRI's portfolio of drug candidates. The collaboration represents a new model for risk-sharing, success-based drug development.

"RxMD's approach is perfect for an early stage company like ours seeking to preserve resources for ongoing discovery," said Marc Hertz, Ph.D., CEO of GRI. "We now have full access to RxMD's world-class drug development capabilities, which will allow us to design and execute development strategies for our drug candidates much more rapidly and efficiently."

"We are very excited to partner with the outstanding discovery team at GRI to help jump start clinical development of their promising portfolio," said Sanjay Shukla, M.D., CEO of RxMD. "There is tremendous potential for GRI's NK T cell research platforms to improve the lives of patients in many therapeutic areas and we look forward to collaborating with GRI to build a pipeline of new medicines for serious un- or under-treated conditions."

About GRI

GlycoRegImmune, Inc., with headquarters in La Jolla, California, is a highly innovative start-up biotech company focused on unique NK T cell-targeted therapies to treat some of the most debilitating diseases of our time. Based on discoveries made at the Torrey Pines Institute for Molecular Studies, GRI's proprietary technologies for inhibiting type I NK T cells and modulating type II NK T cells are being developed as novel approaches to the treatment of human liver, autoimmune and neurodegenerative diseases.

About RxMD

RxMD is a therapeutics company committed to developing and establishing clinical proof of concept for early stage drug candidates. Our collaborative business approach allows partners to access RxMD's clinical development capabilities and expertise. RxMD eschews traditional 'fee for service' relationships, operating instead under success-based outcome agreements. Over the past decade, RxMD has partnered successfully to develop multiple commercialized products for leading global biopharmaceutical companies. For more information, please visit www.rxmd.com.



CONTACT:

RxMD:
Sanjay Shukla, M.D.
646-270-8598
[email protected]
or
GRI:
Marc Hertz, Ph.D.
858-335-0655
[email protected]
or
Media:
BioComm Network, Inc.
Michele Parisi, 925-429-1850
[email protected]

KEYWORDS:   United States  Asia Pacific  North America  California  India

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a 7-2 vote, an FDA panel backed Aimmune’s peanut allergy treatment for approval. It desensitizes patients with increasing doses of peanut protein.

In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.